FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average b	ourden								
-	hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brecher Mark E				2. Issuer Name <b>and</b> Ticker or Trading Symbol LABORATORY CORP OF AMERICA HOLDINGS [ LH ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owne				ner		
(Last) (First) (Middle) 531 SOUTH SPRING STREET				3. Date of Earliest Transaction (Month/Day/Year) 05/24/2012							X Officer (give title below) Other (specify below)  Chief Medical Officer						
(Street) BURLINGTON NC 27215				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting						
(City)	()	State)	(Zip)										Form fi Person		e than	One Report	ing
		Tal	ble I - Non-	-Deriva	ative	e Se	curities	s Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)					es Forr ally (D) ( Following (I) (I		: Direct II Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership				
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
			Table II - D (e						uired, Disp s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode \	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Non- qualified Stock	\$84.86	05/24/2012		1	A		11,400		05/24/2013 <sup>(2)</sup>	05/23/2022	Common Stock	11,400	\$0	11,400	0	D	

## **Explanation of Responses:**

- 1. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan.
- 2. The option vests in three equal annual installments beginning on the date reflected in this column.

/s/ F. Samuel Eberts III,

Attorney-in-Fact for Mark E. 05/29/2012

**Brecher** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.